Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s) - Tebas, Pablo; Zhang, Jiameng; Yarasheski, Kevin; Evans, Scott; Fischl, Margaret A; Shevitz, Abby; Feinberg, Judith; Collier, Ann C; Shikuma, Cecilia; Brizz, Barbara; Sattler, Fred (Journal of acquired immune deficiency syndromes (1999), 2007)
Keywords: Adult; Alkynes; Anti-HIV Agents - adverse effects; Anti-HIV Agents - therapeutic use; Benzoxazines - adverse effects; Benzoxazines - therapeutic use; Body Fat Distribution; Cyclopropanes; Female; HIV Infections - drug therapy; HIV-Associated Lipodystrophy Syndrome - chemically induced; Humans; Lopinavir; Male; Pyrimidinones - adverse effects; Pyrimidinones - therapeutic use; Ritonavir - adverse effects; Ritonavir - therapeutic use; Time Factors